However, its onset of action is too slow for the acute treatment of angina
5 Isosorbide dinitrate and nitroglycerin undergo extensive first-pass hepatic metabolism when Pharmacokinetic studies show that isosorbide mononitrate is rapidly absorbed after oral administration, reaches peak concentrations within an hour
Isosorbide
First approved by the FDA in 1991, isosorbide mononitrate is used for the prevention and
Sustained-release formulations have a slower rate of absorption and can provide therapeutic plasma concentrations of the drug for up to 12 hours
Isosorbide mononitrate: D
Isosorbide mononitrate is cleared by denitration to isosorbide and glucuronidation as the mononitrate, with 96% of the administered dose excreted in the urine within 5 days and only about 1% eliminated The bioavailability of ISDN varies widely, and it undergoes significant first-pass metabolism
All had angiographically proven coronary artery disease and were limited by Isosorbide Mononitrate (ISMN), an organic nitrate and the major biologically active metabolite of isosorbide dinitrate (ISDN), is a vasodilator with effects on both arteries and veins
The average bioavailability of ISDN is about 25%; most studies have observed Isosorbide mononitrate is primarily metabolized by the liver, but unlike oral isosorbide dinitrate, it is not subject to first-pass metabolism
Isosorbide mononitrate is not subject to first pass metabolism by the liver
It works by relaxing the blood vessels and increasing the supply of blood and oxygen to the heart while reducing its workload
Isosorbide-5-mononitrate is cleared by denitration to isosorbide and glucuronidation as the mononitrate, with 96% of the administered dose excreted in the urine within 5 days and Isosorbide mononitrate is primarily metabolized by the liver, but unlike oral isosorbide dinitrate, it is not subject to first-pass metabolism
monoket ® exhibits dose proportionality over the recommended dose range
Isosorbide mononitrate, which has nearly 100% bioavailability, is the exception
The plasma protein binding is less than 5%
Antiplatelet drugs such as tirofiban can reduce the risk of myocardial infarction in